



Weizmann Institute Professor appointed to SciGen Board

Singapore & Sydney: 22 November 2005. The Board of Directors of SciGen Limited (ASX:SIE), has today announced the appointment of Dr. Marian Gorecki to the SciGen Board of Directors.

Dr. Gorecki, a Molecular Biologist and a graduate of MIT in Boston, is the Chairman of SciGen Scientific Advisory Board and has been instrumental in the development of our product portfolio.

His appointment is a key component of the current restructure of the SciGen Board in continued effort to accelerate the growth of the Company.

Dr. Gorecki is the CEO of Mediwound, a pharmaceutical company he founded, and previously the Co-Founder and Managing Director of BioTechnology General Ltd (now Ferring). Dr. Gorecki has more than 18 patents to his name and published 75 scientific papers.

He was appointed Professor at the Weizmann Institute and most recently was given the prestigious award for the most outstanding Scientist for his contribution to the Biotechnology sector in Israel.

About SciGen

SciGen Ltd is a biopharmaceutical company involved in commercialising later stage research. It co-develops and markets biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biogeneric products, which allow for faster entry into the market, as biogeneric products have undergone much of the clinical development and trials required to bring drugs to market. This minimises the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in gaining regulatory approval and bringing products to market

SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange (ASX code SIE). SciGen is headquartered in Singapore, with offices in Australia, USA, Korea, Vietnam, Hong Kong and Philippines and partners in India, China, Indonesia, Israel, Poland, Austria and the Netherlands.

Further information:

Investor Relations and Media	Company
Rebecca Wilson Buchan Consulting +61 2 9237 2800	Saul Mashaal Executive Vice Chairman, Founder & CEO SciGen Ltd.

+61 417 382 391 (mobile)
rwilson@bcg.com.au

+ 61 2 9234 1700
+65 9630 5691 (Mobile)